MGC Pharma (ASX: MXC) has published results from a pre-clinical study on glioblastoma, which showed cannabinoids induce anti-tumour responses and help to fight the cancer.
The study was conducted in collaboration with Slovenian National Institute of Biology (NIB) and University Medical Centre Ljubljana, and supports other published research.
Glioblastoma is the most aggressive and therapeutically non-responsive brain tumour, with survival of patients ranging from 12 to 15 months in spite of improved treatments. This study shows that cannabis derived therapies may be a viable option for patients with glioblastoma, and supports continuing to further in-vitro clinical studies.
The first objective of this pre-clinical study was to evaluate the expression of cannabinoid receptors CB1 and CB2 in a small cohort of glioblastoma (GB) patients-derived tumour tissues, glioblastoma cells and glioblastoma stem cells. Secondly, to identify most effective cannabinoids, their ratios and combinations to alter glioblastoma cell viability and proliferation.
Roby Zomer, Managing Director of MGC Pharma, said “The research into Glioblastoma and the effectiveness of cannabinoid proteins has successfully improved our understanding of what concentrations have the potential to be an adjuvant strategy to reduce the tumour’s growth. This highly encouraging, ground-breaking research is part of our efforts to increase the use of cannabinoids in the treatment of multiple diseases, that are currently unresponsive to conventional medicines.
“The research undertaken in conjunction with academic institutions including Department of Genetic Toxicology and Cancer Biology, the National Institute of Biology in Slovenia, and the Department of Neurosurgery, University Medical Centre Ljubljana, Slovenia, is a key element and differentiator for the Company. It not only serves to increase our understanding of the potential of the cannabinoid products we can produce but also keeps us at the forefront of medical cannabis innovation.”